Abstract

BackgroundmicroRNAs (miRNAs) play both oncogenic and oncostatic roles in leukemia. However, the molecular details underlying miRNA-mediated regulation of their target genes in pediatric B- and T-cell acute lymphoblastic leukemias (ALLs) remain unclear. The present study investigated the relationship between miR-2909 and Kruppel-like factor 4 (KLF4), and its functional relevance to cell cycle progression and immortalization in patients with pediatric ALL.MethodsElevated levels of miR-2909 targeted the tumor suppressor gene KLF4 in pediatric B-cell, but not pediatric T-cell ALL, as detected by pMIR-GFP reporter assay. Expression levels of genes including apoptosis-antagonizing transcription factor (AATF), MYC, B-cell lymphoma (BCL3), P21 CIP , CCND1 and SP1 in B- and T-cells from patients with pediatric ALL were compared with control levels using real-time quantitative reverse transcription polymerase chain reaction, western blotting, and reporter assays.ResultsWe identified two novel mutations in KLF4 in pediatric T-ALL. A mutation in the 3′ untranslated region of the KLF4 gene resulted in loss of miR-2909-mediated regulation, while mutation in its first or third zinc-finger motif (Zf1/Zf3) rendered KLF4 transcriptionally inactive. This mutation was a frameshift mutation resulting in alteration of the Zf3 motif sequence in the mutant KLF4 protein in all pediatric T-ALL samples. Homology models, docking studies and promoter activity of its target gene P21 CIP confirmed the lack of function of the mutant KLF4 protein in pediatric T-ALL. Moreover, the inability of miR-2909 to regulate KLF4 and its downstream genes controlling cell cycle and apoptosis in T-cell but not in B-ALL was verified by antagomiR-2909 transfection. Comprehensive sequence analysis of KLF4 identified the predominance of isoform 1 (~55 kDa) in most patients with pediatric B-ALL, while those with pediatric T-ALL expressed isoform 2 (~51 kDa).ConclusionsThis study identified a novel miR-2909-KLF4 molecular axis able to differentiate between the pathogeneses of pediatric B- and T-cell ALLs, and which may represent a new diagnostic/prognostic marker.

Highlights

  • MicroRNAs play both oncogenic and oncostatic roles in leukemia

  • Increased miR-2909 expression was always accompanied by significant downregulation of Kruppel-like factor 4 (KLF4) mRNA and protein in pediatric B-Acute lymphoblastic leukemia (ALL) compared with controls, indicating that miR-2909 may regulate the expression of KLF4 by targeting its 3′untranslated region (UTR) (Figure 1C and D)

  • To the best of our knowledge, the results provide the first evidence for two novel mutations in the KLF4 gene in T-cell lineage acute lymphoblastic leukemia (T-ALL): a mutation in the 3′UTR resulted in loss of miR-2909-mediated regulation, and mutation in the First zinc finger motif (Zf1)/Third zinc finger motif (Zf3) motif rendered KLF4 transcriptionally inactive

Read more

Summary

Introduction

MicroRNAs (miRNAs) play both oncogenic and oncostatic roles in leukemia. the molecular details underlying miRNA-mediated regulation of their target genes in pediatric B- and T-cell acute lymphoblastic leukemias (ALLs) remain unclear. Acute lymphoblastic leukemia (ALL) is widely recognized as the most prevalent pediatric leukemia [1]; the genomic mechanisms responsible for the uncontrolled cell proliferation coupled with cell immortalization remain unknown [2]. In this context, the genes for apoptosisantagonizing transcription factor (AATF) and Kruppel like factor 4 (KLF4) have assumed importance. AATF provides a critical link between cell cycle progression, check-point control, and apoptosis [3], and encodes the novel microRNA (miRNA) miR-2909, which regulates genes involved in inflammation, cell cycle, and immune response [4,5,6]. KLF4 mRNA has been shown to be targeted by miR-130a and 135b in M1 acute myeloid leukemic blasts, and silencing of KLF4 arrested the maturation of blood cells at an early progenitor stage [10]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call